References
- Podell R. Lipids, nutrition and coronary heart disease. In: Podell R, Stewart M. eds. Primary prevention of coronary heart disease: a practical guide for the clinician. Reading, MA: Addison-Wesley, 1983: 78–114
- Podell R. The Multiple Risk Factor Intervention Trial (MRFIT): summary of findings and preliminary Interpretation, in: Podell. Stewart, eds. 1 pp 326–34
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. n. The relationship of reduction In incidence of coronary heart disease to cholesterol lowering. JAMA 1984: 251(3): 365–74
- Committee of Principal Investigators, WHO Cloflbrate Trial. A cooperative trial In the primary prevention of lschaemic heart disease using cloflbrate. Br Heart J 1978: 40(10): 1069–118
- Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high In unsaturated fat In preventing complications of atherosclerosis. Circulation 1969; 40(Suppl 2): 1–63
- Group of Physicians of the Newcastle Upon Tyne Region. Trial of clofibrate In the treatment of ischaemic heart disease. Br Med J 1971: 4(Dec 25): 767–75
- Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using cloflbrate. Br Med J 1971; 4(Dec 25): 775–84
- Coronary Drag Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975: 231 (4): 360–81
- Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxlne. JAMA 1972: 220: 996–1008
- Stamler J, Pick R, Katz LN, et al. Effectiveness of estrogens for therapy of myocardial Infarction In middle-age men. JAMA 1963; 183(Feb 23): 632–8
- Coronary Drug Project Research Group. The Coronary Drug Project: Initial findings leading to modifications of its research protocol. JAMA 1970: 214(7): 1303–13
- Coronary Drag Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5 mg estrogen group. JAMA 1973: 226(6): 652–7.
- Dorr AE, Gundersen K, Schneider JC Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients: effect on serum cholesterol and mortality. J Chronic Dis 1978: 31(1): 5–14
- Turpeinen O, Karvonen MJ, Pekkarinen M, et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study, Int J Epldemiol 1979;8(2): 99–118
- Rosenhamer G. Carlson LA. Effect of combined clofibrate-nicotlnlc acid treatment in Ischemic heart disease: an interim report. Atherosclerosis 1980: 37(1): 129–42
- Hjermann I, Velve Byre K, Holme I, et al. Effect of diet and smoking Intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial In healthy men. Lancet 1981: 2(8259): 1303–10
- Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982: 248(12): 1465–77
- Levy RI. The influence of cholestyramine-induced lipid changes on coronary artery disease progression: the NHLBI Type n Coronary Intervention Study. (Abstr) Circulation 1983: 68(Suppl 3): 188
- Physicians' desk reference. 38th ed. Oradell, NJ: Medical Economics. 1984: 1222–4
- Handbook of coronary risk probability. Dallas: American Heart Assn. 1972